Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 194.11 |
| Open | 193.34 |
| Bid | 192.84 x 300 |
| Ask | 193.08 x 300 |
| Day's Range | 192.75 - 195.86 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,201,566 |
| Market Cap | 28.081B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 24.21 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
Despite Revenue Decline, Non-GAAP EPS Growth and Strategic Initiatives Show Promise
- Reuters
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
The company also said its Alzheimer's drug Leqembi, developed with Japanese partner Eisai, recorded global sales of about $19 million, nearly tripling from the fourth quarter of 2023. The number of patients on Leqembi have increased nearly 2.5 times since the end of 2023, Biogen said. Biogen and Eisai also intend to increase their sales force as they aim for 100,000 patients by 2026.
- Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and could help Biogen stock reverse a recent downtrend.
© 2024 Yahoo. All rights reserved.